Hilleman Laboratories' CEO, Dr Davinder Gill, believes that the venture's heat-stable rotavirus vaccine can potentially match the proposed $1 pricing of Bharat Biotech's Rotavac backed with "appropriate scale" and a robust demand forecast.
Hilleman CEO On $1 Rotavirus Vaccine Pricing And GSK's Mosquirix
Hilleman Laboratories' CEO, Dr Davinder Gill, believes that the venture's heat-stable rotavirus vaccine can potentially match the proposed $1 pricing of Bharat Biotech's Rotavac backed with "appropriate scale" and a robust demand forecast.
More from Alimentary/Metabolic
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.